Yvette Cooper became the UK's health secretary in July 2026, and the reshuffle around her appointment reshaped who pharmaceutical, medtech and NHS-facing teams need to track in government.
Companies should revisit relationships and engagement plans built around the previous ministerial and NHS England structures, and treat the neighbourhood contract consultation as a near-term priority rather than a background policy development.
Yvette Cooper became the UK's third health and social care secretary in ten weeks when prime minister Andy Burnham appointed her on 20 July 2026. She replaced James Murray, who had held the post since Wes Streeting resigned on 14 May citing a loss of confidence in Keir Starmer's leadership. Starmer resigned as prime minister three weeks later, and Burnham won the leadership after securing a Commons seat in a by-election in his old Greater Manchester patch.
For pharmaceutical, medtech and NHS-facing teams, that timeline matters less than what came with it. Below Cooper, the ministerial team responsible for medtech, medicines and life sciences changed hands. The department that used to own UK science and technology policy no longer exists. And several of the operational questions that determine how companies engage the NHS, including who holds the contract for neighbourhood health services, are being settled this summer through consultations that have had less attention than the cabinet list.
Cooper's own background offers some clue to her priorities. She was a junior health minister in 1999, before later serving as home secretary and, until this reshuffle, foreign secretary. She has said she is looking forward to working on maternity services and social care, ‘27 years after I worked on the first NHS Cancer Plan as a junior health minister’.
The team beneath her is now confirmed:
Frith's brief is the one commercial teams should watch most closely: medtech, medicines, and research and innovation now sit with a single junior minister. A further update in August confirmed that dentistry, NHS data and technology, and men's health also sit within his portfolio. Stephen Kinnock, the outgoing pharmacy minister, moved to become secretary of state for Wales.
The bigger structural change sits outside DHSC. Burnham abolished the Department for Science, Innovation and Technology soon after taking office, moving its functions into a new Department for Business, Innovation, Science and Trade under Jonathan Reynolds, with some responsibilities also going to a strengthened Department for Culture, Media and Sport and the Cabinet Office. Patrick Vallance stepped down as science minister and Liz Kendall left as science secretary. Chris McDonald, an industrial chemist and former chief executive of the Materials Processing Institute, took the science brief and joined DHSC in a joint appointment spanning both departments.
Reaction was split. ABPI chief executive Richard Torbett called Vallance's departure ‘a loss,’ pointing to his role in supporting the UK's life sciences reputation internationally. Royal Society president Paul Nurse warned that science must not become a ‘junior partner’ inside the merged department. The Bio Industry Association took a more optimistic view of McDonald's joint role, welcoming a minister who spans health and business as a way of keeping the life sciences ecosystem aligned rather than split across departmental boundaries.
Which view proves closer to the mark depends on how DBIST, DHSC and the Treasury divide up funding decisions that used to sit inside one department. A joint minister answers a coordination problem in principle; it is not yet evidence that the coordination will happen in practice.
Sector bodies have mostly asked for stability rather than change. The NHS Alliance welcomed Cooper's appointment and called on her to ‘continue with the current direction of travel’ on the 10 Year Health Plan, while backing Burnham's commitment to social care reform as ‘long overdue’. When Murray took over from Streeting in May, public affairs consultant Chris Whitehouse predicted ‘business as usual’ for medtech, expecting value-based procurement to continue unchanged.
That reading has held up reasonably well: the 10 Year Health Plan's three shifts, from hospital to community, analogue to digital and sickness to prevention, remain the stated framework, and Cooper inherits rather than rewrites them. But continuity of stated policy is not the same as continuity of delivery capacity. The King's Fund notes that Cooper also inherits the Health Bill, which abolishes NHS England and centralises power with the Secretary of State, alongside an unresolved social care settlement and a delayed 10-year workforce plan. Three secretaries of state and a dissolved department within ten weeks is not the backdrop most delivery plans are built for.
That reading looks less secure once ICB boundaries themselves are back in play. On 31 July 2026, the Cabinet Office's Rewiring the State statement set out plans to align integrated care boards with strategic authority boundaries by the end of this Parliament, in some areas as late as August 2029, alongside similar realignment for police forces and fire and rescue services. Some ICBs have already begun confirming what that means locally: North East and North Cumbria ICB is realigning by 2028, with North Cumbria transferring into Lancashire and South Cumbria ICB. Organisations that have just absorbed a round of cluster mergers and running-cost cuts now face a second wave of boundary changes before 2029, a different order of disruption to a change of Secretary of State.
The clearest illustration of that gap between policy and delivery sits in neighbourhood health. Industry commentator Scott McKenzie has argued that the 10 Year Health Plan established Integrated Neighbourhood Teams as the operating model for the shift out of hospitals, but never settled who employs the neighbourhood workforce, who holds the contract, or who carries the financial risk when demand exceeds what was budgeted.
NHS England opened a consultation on exactly that question on 16 July 2026, four days before Cooper's appointment. It sets out three routes for commissioning neighbourhood services. Practices and PCNs can stay on the existing national DES, which protects entitlements but caps local variation and runs on an annual cycle. They can hold a direct Single Neighbourhood Provider (SNP) contract with their local commissioner, trading national protection for multi-year planning and local flexibility. Or a Multi-Neighbourhood Provider (MNP) can hold the head contract and sub-contract into individual neighbourhoods, adding standard sub-contract terms and an intermediary between practice and commissioner.
No new money is attached to any of the three options, though minimum investment is protected. The consultation closes 10 September 2026 and will feed into firmer proposals later in the year. It amounts to the first live attempt to answer a question that a change of health secretary cannot answer on its own.
Four things follow, three from the reshuffle and one from the consultation running alongside it.
Each of those relationships is being redrawn at roughly the same time, which is unusual even for a department that changes ministers often.
Scott McKenzie's assessment of Cooper's in-tray applies just as well to how industry should read this reshuffle. Wes Streeting set the direction for the NHS, and each of his successors has had less time to do anything with it than the one before. Cooper's real test as health secretary, and the industry's signal to watch, is not the reshuffle itself but whether the delivery architecture behind it, the neighbourhood contracts, the workforce plan, the funding attached to the left shift, gets built before the next reshuffle arrives.
CHASE works with pharmaceutical, medtech and NHS-facing companies to translate this kind of policy change into practical commercial and market access strategy. If the ministerial and contractual changes covered here affect how your teams engage the NHS, our insights and market access team can help you work through what to prioritise.
Yvette Cooper became health secretary on 20 July 2026, the third person to hold the post in ten weeks after Wes Streeting resigned in May and James Murray served as interim secretary. She previously served as home secretary and foreign secretary.
James Frith, Parliamentary Under-Secretary of State for Health Innovation, holds the DHSC brief for medtech, medicines, research and innovation, alongside major and long-term conditions, dentistry and NHS data and technology. His office is now the practical point of contact for industry engagement on these areas.
Prime Minister Andy Burnham abolished DSIT shortly after taking office, moving its functions into a new Department for Business, Innovation, Science and Trade. ABPI called the departure of science minister Patrick Vallance a loss for UK life sciences policy, while Chris McDonald took on a joint DHSC and DBIST brief.
NHS England's consultation, open until 10 September 2026, sets out three routes for commissioning neighbourhood services: the existing national DES, a direct Single Neighbourhood Provider (SNP) contract, or a Multi-Neighbourhood Provider (MNP) model. The outcome will determine which local organisations companies need relationships with.
Yes. The Cabinet Office's Rewiring the State statement, published 31 July 2026, set out plans to align ICB boundaries with strategic authority footprints by the end of this Parliament, in some areas by August 2029. North East and North Cumbria ICB has already confirmed its new footprint.
Explore our latest thinking, event updates and industry insights to stay informed.
The UK has real strengths in life sciences, but Streeting’s resignation raises new questions about reform continuity. CHASE examines.
CHASE publishes its 2025 gender pay gap report. Read our analysis of the data, what is driving it, and how the picture compares across life sciences and the NHS
The National Cancer Plan for England sets a ten-year strategy to transform outcomes for people diagnosed with cancer by 2035, by reforming the care model.
.svg)
